The biggest names in diabetes tech gathered in New Orleans last weekend for the American Diabetes Association’s 86th Scientific Sessions (ADA 2026). Clinical findings supporting next-generation automated insulin delivery platforms, continuous glucose monitors (CGMs) and all kinds of other technologies were on display in New Orleans. BTIG analysts Marie Thibault, Alexandra Pang and Sam Eiber […]
Dexcom
Dexcom CEO Jake Leach talks Nutrisense acquisition, type 2 push, next-gen G8
Nearly halfway through 2026, the milestones are already stacking up for continuous glucose monitor (CGM) maker Dexcom (Nadsaq:DXCM). President and CEO Jake Leach took over the corner office in January. In the months that have followed, highlights include the unveiling of the next-generation G8 sensor system, the launch of the Flex sensor platform outside the […]
Dexcom study highlights benefits of G7 CGM in non-insulin type 2 diabetes
Dexcom (Nasdaq:DXCM) today announced findings from a study demonstrating the benefits of its G7 CGM in type 2 diabetes. The CONNECT study evaluated the current-generation G7 continuous glucose monitor (CGM) in people with type 2 diabetes not using insulin. It compared this population to a routine care control group using self-monitoring of blood glucose. Researchers shared […]
Dexcom to acquire wellness tracking company Nutrisense, launch enhanced Stelo app
Dexcom (Nasdaq:DXCM) announced today that entered into an agreement to acquire Nutrisense and shared plans for upgrades to its Stelo sensor. San Diego-based Dexcom expects its deal to buy Nutrisense for an undisclosed amount in the coming weeks. With the acquisition, the continuous glucose monitor (CGM) maker plans to further expand its ability to support […]
MyLife integrates MyLoop automated insulin pump with Dexcom G7
MyLife Diabetes Care, CamDiab and Dexcom today announced the integration of the G7 continuous glucose monitor (CGM) into the MyLoop system. MyLoop (previously MyLife Loop), an automated insulin delivery (AID) system, is powered by the CamAPS FX app. The system already integrated with the previous-generation Dexcom G6, as well as Abbott’s FreeStyle Libre 3 Plus. […]
Dexcom says third party stole, sold scrapped G7 CGM lots
Dexcom (Nasdaq:DXCM) announced today that third parties stole and sold certain G7 continuous glucose monitor (CGM) lots designated as scrap. The company identified the lots — stolen during the destruction process — through ongoing quality and accounting reviews. At this moment, the company reports two G7 lots (1725204004 and 1725069002) as stolen, sold and used by some […]
Dexcom launches Flex CGM for type 2 diabetes in Germany
Dexcom (Nasdaq:DXCM) today announced the launch of Dexcom Flex, a new continuous glucose monitor (CGM) for adults with type 2 diabetes. Flex targets adults with type 2 not on intensive insulin therapy, providing an option for those on basal insulin, oral medications or GLP-1 receptor agonists. San Diego–based Dexcom says its new system, set to […]
Dexcom unveils next-gen G8 CGM system, CEO Jake Leach explains new tech
Dexcom (Nasdaq:DXCM) today unveiled its next-generation continuous glucose monitor (CGM), the G8 system, at its Investor Day event. San Diego-based Dexcom CEO Jake Leach previously told Drug Delivery Business News that the G8 would offer a “much smaller wearable” in a step-change from the company’s current-generation G7 system. At the company’s investor day, Leach offered more […]
ViCentra launches smartphone-controlled Kaleido automated insulin patch pump system
ViCentra announced today that it launched its Kaleido smartphone-controlled hybrid closed-loop insulin delivery system in Europe. The new system combines the company’s Kaleido patch pump with Diabeloop’s DBLG2 algorithm and the Dexcom G7 continuous glucose monitor (CGM). It comes on the heels of Diabeloop’s CE mark for the next-generation algorithm paired with G7, announced yesterday. […]
Diabeloop gets CE mark for next-gen algorithm paired with Dexcom G7, ViCentra Kaleido
Diabeloop announced today that it received CE mark approval for its latest automated insulin delivery (AID) platform, DBLG2. CE mark approval comes not long after FDA approval in December 2025. The algorithm initially received CE mark last year but now has European approval for compatibility with next-generation devices. With clearance for DBLG2, integrated with the […]
